1 Department of Medical Imaging, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huai'an, China.
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819842944. doi: 10.1177/1533033819842944.
To determine whether change in apparent diffusion coefficient value could predict early response to chemotherapy in breast cancer liver metastases.
We retrospectively studied 42 patients (86 lesions) with breast cancer liver metastases who had undergone conventional magnetic resonance imaging and diffusion-weighted imaging (b = 0.700 s/mm) before and after chemotherapy. Maximum diameter and mean apparent diffusion coefficient value (×10 mm/s) of liver metastases from breast cancer were evaluated. The grouping reference was based on magnetic resonance imaging according to Response Evaluation Criteria in Solid Tumors (RECIST). Analysis of variance and receiver-operating characteristic analyses were performed.
Eighty-six metastases were classified as 40 responders and 46 nonresponders. A statistically significant correlation was found between prechemotherapy and postchemotherapy apparent diffusion coefficient values in responders, which were 0.9 ± 0.16 × 10 mm/s, 1.05 ± 0.12 × 10 mm/s, 1.26 ± 0.12 × 10 mm/s, and 1.33 ± 0.87 × 10 mm/s, respectively. No statistically significant difference was found between prechemotherapy and postchemotherapy apparent diffusion coefficient values in nonresponders. Differences were statistically significant between responders and nonresponders at prechemotherapy, 2 weeks after chemotherapy, and 4 weeks after chemotherapy ( P = 0.014, P = .001, and P = .000, respectively). Receiver operating characteristic curves showed that apparent diffusion coefficient values could predict treatment response early at 2 weeks after chemotherapy with 64.5% sensitivity and 91.8% specificity.
The change in apparent diffusion coefficient value may be a sensitive indicator to predict early response to chemotherapy in breast cancer liver metastases.
探讨表观扩散系数值的变化能否预测乳腺癌肝转移化疗的早期疗效。
回顾性分析 42 例(86 个病灶)乳腺癌肝转移患者化疗前后的常规磁共振成像和扩散加权成像资料(b 值为 0.700 s/mm)。测量乳腺癌肝转移病灶的最大直径和平均表观扩散系数值(×10 mm/s)。分组依据为根据实体瘤疗效评价标准(RECIST)的磁共振成像表现。采用方差分析和受试者工作特征曲线分析。
86 个病灶中 40 个为化疗有效,46 个为化疗无效。化疗有效的患者化疗前后的表观扩散系数值具有显著相关性,分别为 0.9±0.16×10 mm/s、1.05±0.12×10 mm/s、1.26±0.12×10 mm/s、1.33±0.87×10 mm/s。化疗无效的患者化疗前后的表观扩散系数值无显著差异。化疗有效和无效患者在化疗前、化疗后 2 周、化疗后 4 周的表观扩散系数值差异均有统计学意义(P=0.014、P=0.001、P=0.000)。受试者工作特征曲线分析显示,表观扩散系数值在化疗后 2 周时对预测疗效的效能最高,敏感度为 64.5%,特异度为 91.8%。
表观扩散系数值的变化可能是预测乳腺癌肝转移化疗早期疗效的敏感指标。